跳至主要内容
临床试验/KCT0008637
KCT0008637已完成Unknown

Observational study(OS) for efficacy and safety of Fybro® in patients with idiopathic pulmonary fibrosis (IPF)

Yungjin Pharm0 个研究点目标入组 360 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
o Limit 至 o Limit(—)
性别
All

入选标准

  • 1. Patients who were diagnosed with idiopathic pulmonary fibrosis, administered Fybro for the first time.
  • 2. Signed informed consent form to participate the study.

排除标准

  • 1. Those who are contraindicated for administration of this drug according to approval drug information by MFDS
  • 1) Patients who are hypersensitive to the main ingredient or additives of this drug
  • 2) Patients with severe hepatic impairment or end-stage epilepsy
  • 3) Patients with severe renal impairment or end-stage renal disease requiring dialysis
  • 4) Patients receiving concomitant fluvoxamine
  • 5) Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • 2. A person who uses it for purposes other than approval indication
  • 3. Patients who are participating in other clinical trials

研究者

发起方
Yungjin Pharm

相似试验